StockData
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD) stock

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.01−0.60 (-16.62%)

Close on Nov 17, 2026Market cap $321.08MP/E –Yield –

Relmada Therapeutics market cap

Market capitalization is the share price multiplied by the number of shares outstanding.

Relmada Therapeutics's market cap was $472.55M on Nov 11, 2026, against $149.69M a year earlier. Over the last 5 years it ranged from $5.07M to $1.09B, with a median of $109.56M.

Market Cap at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$472.55M+194.8%
2025Dec 31, 2025$160.32M+921.7%
2024Dec 31, 2024$15.69M-87.4%
2023Dec 29, 2023$124.61M+2359.0%
2022Dec 30, 2022$5.07M-98.7%
2021Dec 31, 2021$394.31M+26.2%
2020Dec 31, 2020$312.51M-17.8%
2019Dec 31, 2019$380.04M+2533.3%
2018Dec 31, 2018$14.43M+53.4%
2017Dec 29, 2017$9.41M-28.3%
2016Dec 30, 2016$13.12M-52.4%
2015Dec 31, 2015$27.54M+79.1%
2014Dec 31, 2014$15.37M–

More Relmada Therapeutics figures

See a number that looks wrong?